This page is updated frequently with new Dysfunction-related patent applications.
|Methods and systems for assessing infertility as a result of declining ovarian reserve and function|
The present invention relates to methods and systems for assessing ovarian reserve and function in a female subject and informing course of treatment thereof. The invention provides methods for assessing ovarian reserve and function by analyzing both clinical and genetic data/characteristics from a female subject.
|Methods of using anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunity|
The present application relates to anti-pd-l1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance t-cell function to upregulate cell-mediated immune responses and for the treatment of t cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.. .
|Multifunctional nitroxide derivatives and uses thereof|
Multifunctional nitroxide derivatives contain a potassium channel opener and a reactive oxygen species (ros) degradation catalyst that can act as an anti-oxidant. Pharmaceutical compositions can include the derivatives.
Radikal Therapeutics Inc
|Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells|
The disclosure is directed to the use of nonviable pluripotent stem cells to improve age-related declines in tissue and organ function. In one aspect, nonviable pluripotent stem cells are used to improve cognition in a subject in need thereof.
|Compositions and methods for treatment of lung dysfunction|
Described are compositions and methods for the treatment, prevention, or amelioration of a symptom of an airway disorder. In certain aspects, the airway disorder may be one characterized by one or more conditions, such as goblet cell metaplasia, lung tissue inflammation, increased airway hyperresponsiveness, mucus hyperplasia, decreased airway resistance, and increased production of pro-inflammatory cytokines.
Children's Hospital Medical Center
|Therapy to treat pelvic floor dysfunction and/or pain|
In some examples, the disclosure describes devices, systems, and techniques for treating pain and/or pelvic floor dysfunction of a patient. For example, a method for treating pelvic floor dysfunction in a patient may include delivering, via a medical device, a therapy to one or more nerve fibers, wherein the therapy is configured to at least temporarily deactivate the one or more nerve fibers; and determining that the one or more nerve fibers was at least temporarily deactivated by delivering the therapy..
|Substituted prolines / piperidines as orexin receptor antagonists|
The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
Eolas Therapeutics, Inc.
|Medical device and methods of monitoring a patient with renal dysfunction|
Embodiments relate to a method of monitoring physiological parameters of a patient with renal dysfunction. The method includes electrically connecting one or more medical device electrodes with a measurement site of a patient, generating one or more first stimulation signals sufficient to provide input physiological parameters specific to the patient, measuring one or more first bioimpedance values from the generated signals, analyzing at least one of the input physiological parameters within the one or more first bioimpedance values and generating a personalized dialysis program.
Medtronic Monitoring, Inc.
|Method of therapy and diagnosis of endothelial dysfunction|
The invention discloses a method of therapy of endothelial dysfunction, by administering microrna let-7g to a subject in need, wherein the microrna let-7g inhibits smad2 transcription factor from activation and translocation into nucleus, thereby decreasing monocyte cell adhesion, inflammation and thrombosis and increasing angiogenesis.. .
Kaohsiung Medical University
|Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction|
Compositions comprising one or more cytokines and methods for their use in inhibiting and/or alleviating effects of radiation therapy and/or chemotherapy and/or acute radiation syndrome in a subject in need thereof are provided.. .
A composition for preventing, treating, and improving of voiding dysfunction comprising extract of piper longum l.
The present invention relates to a pharmaceutical composition for preventing or treating voiding dysfunction and a health functional food for preventing or improving of voiding dysfunction, comprising extract of piper longum l. As an active ingredient.
Dong Wha Pharm. Co., Ltd.
Pulmonary hypertension biomarker
Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension.
Antibody-based depletion of antigen-presenting cells and dendritic cells
Disclosed herein are methods and compositions comprising anti-cd74 and/or anti-hla-dr antibodies for treatment of gvhd and other immune dysfunction diseases. In preferred embodiments, the anti-cd74 and/or anti-hla-dr antibodies are effective to deplete antigen-presenting cells, such as dendritic cells.
Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom..
M.g. Therapeutics, Ltd.
Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide
This invention is about the compositions and methods for assessing and treating vascular endothelial dysfunction. Various aspects provide a method for treatment of vascular endothelial dysfunction, comprising administering a composition comprising nicotinamide mononucleotide and a pharmaceutical excipient to a subject.
The Regents Of The University Of Colorado, A Body Corporate
Pulmonary expansion therapy devices
A pulmonary expansion therapy (pxt) device may be a handheld device that covers specific lung fields and may generate negative pressure fields locally. The device also may provide percussion therapy for airway clearance.
Novel compounds as diacylglycerol acyltransferase inhibitors
This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Methods and kits for treating and classifying individuals
The present disclosure provides methods and kits for treating and classifying individuals at risk of or suffering from a neurological and/or mitochondrial dysfunction or disorder. In general, the individuals are treated and/or classified based on the presence of a loss-of-function mutation in nuclear dna encoding one or more proteins selected from the group consisting of aldh1l1, aldh1l2, folr1, fpgs, gcsh, gldc, mthfd1, mthfd1l, mthfd2, mthfd2l, mthfs, mtrr, shmt1, shmt2 and slc25a32.
Courtagen Life Sciences, Inc.
Crystal form iii of (s)-oxiracetam, preparation method and use thereof
(s)-4-hydroxy-2-oxo-1-pyrrolidine crystal form iii (called crystal form iii of (s)-oxiracetam for short) has diffraction peaks at diffraction angles 2θ, wherein the diffraction angles 2θ are equal to 10.54, 13.70, 14.44, 15.60, 17.12, 18.88, 19.24, 20.66, 20.84, 21.18, 21.82, 22.94, 23.24, 24.88, 27.20, 27.48, 28.24, 30.46, 30.80, 31.52, 32.00, 32.34, 32.90, 33.20, 34.40, 34.62, 37.30, 37.50, 38.28, 38.96, and 40.02°. The (s)-oxiracetam crystal form iii of the present invention has an obvious effect on memory dysfunction, is dissolved in water fast, has high bioavailability, and can be used to prepare various pharmaceutical compositions.
Chongqing Runze Pharmaceutical Company Limited
Methods to concurrently stimulate different brain targets
A method for treating a patient having a dysfunction using a stimulation lead within the brain of a patient is provided. The stimulation lead carries a plurality of electrodes adjacent to a plurality of brain regions.
Boston Scientific Neurornodulation Corporation
Method of treating insomnia
Methods for treating insomnia are disclosed. The methods are directed to administering a pharmaceutically effective amount of phosphodiesterase 5 (pde5) inhibitor to a male individual suffering from insomnia.
Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage
The objective of the present invention is to provide a new medicinal use of clarithromycin. The present invention is a therapeutic agent or a preventive agent for meibomian gland dysfunction or meibomian gland blockage and comprises clarithromycin as an active ingredient.
Santen Pharmaceutical Co., Ltd.
Methods and apparatuses for treatment of meibomian gland dysfunction
Apparatus and methods for treating dry eye include an energy source configured to apply energy to an obstruction located in a meibomian gland of a patient's eyelid. The apparatus also comprises an insulator configured to be positioned between a rear portion of the patient's eyelid and a surface of the patient's eyeball.
Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof
The present invention relates to pyrazolopyrimidinone compounds as pde5 inhibitors with better ic50 value, good in vivo efficacy and pk profile and a process for the preparation thereof. The present invention covers the pyrazolo pyrimidinone based compounds that have been designed, synthesized and screened for pde5 inhibitory activity and its pde5 inhibitory potential is provided in this invention.
Council Of Scientific & Industrial Research
Managing therapy delivery based on physiological markers
Devices, systems, and methods may manage therapy delivery to a patient based on one or more physiological markers. In some examples, a method includes detecting a physiological marker that occurs prior in time to a dysfunctional phase of a physiological cycle, wherein a dysfunctional state of the physiological cycle occurs during the dysfunctional phase without treatment, responsive to detecting the physiological marker, initiating a first phase of the physiological cycle having a duration of time.
Methods and compositions for mitochondrial replacement therapy
The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities..
The Mclean Hospital Corporation
Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gbs), metabolic syndrome, muscular dystrophy or duchenne muscular dystrophy (dmd), severe burns, aging, amyotrophic lateral sclerosis (als), friedreich's ataxia, batten disease, alzheimer's disease, optic neuritis, leber's hereditary optic neuropathy (lhon), autism, rett syndrome, batten disease, angelman's syndrome, leigh disease, fragile-x syndrome, depression, parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous bdnf expression with dnp treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. Dnp was administered to mice daily over a range of doses, and subsequently bdnf expression in the brain showed a dose dependent and non-linear increase in expression..
Mitochon Pharmaceuticals, Inc.
High throughput biochemical fluorometric measuring hdl redox activity
In various embodiments, a new, robust fluorometric cell-free biochemical assay that measures hdl redox activity (hra) is provided. In certain embodiments the assay is based on the oxidation of the fluorochrome amplex® red in the presence of hrp.
The Regents Of The University Of California
Use of aromatic-cationic peptides to treat cholesterol-induced mitochondrial dysfunction
The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in inhibiting cholesterol-induced cytochrome c peroxidase activity, promoting reduction of cytochrome c, and inhibition of cardiolipin peroxidation to treat, prevent or ameliorate cholesterol-induced mitochondrial dysfunction..
Heteroaromatic compounds and their use as dopamine d1 ligands
And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mcl, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .
Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
The invention relates generally to neuroprotection and repair in neurological disorders involving tan dysfunction (including alzheimer's disease). The invention describes and includes a direct interaction between proteins fkbp52 mid tau.
Institut National De La Sante Et De La Recherche Medicale (inserm)
Use of a composition comprising arabic gum (ag) for improving gut impermeability
The use of a nutritional composition including arabic gum (ag) improves gut impermeability. The nutritional composition also improves conditions like abdominal pain, chronic or not, insomnia, bloating, flatulence, shortness of breath, gluten intolerance, malnutrition, muscle cramps, multiple chemical sensitivities, muscle pain, myofascial pain, mood swings, poor exercise tolerance, poor immunity, poor memory, recurrent skin rashes, brittle nails, hair loss, food allergies, constipation, diarrhea, liver dysfunction, brain fatigue, abdominal spasms, constant hunger pains, depleted appetite, irritable bowel syndrome, chemotherapy, food allergies, acne, liver dysfunction or inflammation of the bowel..
Micro/nano composite drug delivery formulations and uses thereof
Disclosed are micro/nano composite drug delivery compositions for use in diagnosis, prophylaxis, treatment and/or amelioration of one or more symptoms of a mammalian disease, disorder, dysfunction, or abnormal condition. In illustrative embodiments, pharmaceutical formulations comprising these composites are provided that are useful in methods for targeting selected mammalian cells and tissues, particularly human lung tissue, and delivering one or more therapeutic agents, particularly in the treatment of human lung cancers, such as melanoma lung metastases..
The Methodist Hospital
(b) a non-human animal obtained by producing a serially transplanted chimeric non-human animal via two steps, a first step being a step of producing a primary chimeric non-human animal by transplantation of human hepatocytes to an immunodeficient non-human animal with liver dysfunction, a second step being a step of transplanting the human hepatocytes grown in the body of the primary chimeric non-human animal to an immunodeficient non-human animal with liver dysfunction, the second step being performed one or more times; and subsequently administering a purine base-containing substance to the serially transplanted chimeric non-human animal.. .
Methods and materials for characterizing intestinal barrier function
The present invention the present invention provides methods and materials related to the characterization of intestinal barrier function, and related methods for preventing and/or treating intestinal barrier dysfunction. In particular, the present invention provides methods and materials for characterizing intestinal barrier function within mammals (e.g., humans) through determining the level, presence, and/or frequency of biomarkers for intestinal function (e.g., functional enterocyte mass, enterocyte integrity, paracellular tight junction function, gut inflammation) within a biological sample..
The Arizona Board Of Regents On Behalf Of The University Of Arizona
Treatment of erectile dysfunction and other indications
The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment.
Strategic Science & Technologies, Llc
Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
The invention relates to a compound having ssao/vap-1 inhibitor activity for use in the treatment of hyperalgesia and allodynia implicated in traumatic neuropathy or neurogenic inflammation. Accordingly, the invention relates to a compound having ssao/vap-1 inhibitor activity for use in the inhibition of pathological activation and dysfunctions of peptidergic sensory nerves caused by mechanical damage or chemical activation of peptidergic sensory nerves in neurogenic inflammation..
Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
Compositions and methods are provided for treating a patient suffering from a disease associated with endothelial dysfunction by administering to the patient a pharmaceutical composition containing an effective amount of a synthetic collagen binding peptidoglycan.. .
Purdue Research Foundation
Agent for preventing or ameliorating vascular endothelial malfunction
An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e.g., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e.g., stiff shoulders, excessive sensitivity to cold, swelling, erectile dysfunction, rough skin and decrease in exercise performance due to skeletal muscle hypoactivity), which has an improved no production enhancing effect is provided. A no production enhancer comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients.
Kyowa Hakko Bio Co., Ltd.
Method for treating or preventing a pancreatic dysfunction
The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject stro-1+ cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas..
Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
The invention relates to the field of female sexual dysfunction. It specifically relates to the influence of the combination of testosterone or an analog thereof and tadalafil on sexual health in female subjects with female sexual dysfunction (such as female sexual arousal disorder (fsad) or female sexual desire disorder (fsdd)).
Eb Ip Lybrido B.v.
Neuro-protective agents and uses thereof (as amended)
Use of 5α-androstane-3β,5,6β-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5α-androstane-3β,5,6β-triol treatment can effectively reduce vasogenic edema of brain tissue of macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness..
Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Selective opioid compounds
Which relates to mophinan compounds useful as μ, δ and/or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.. .
Congestive Heart Failure
Follow us on Twitter
This listing is a sample listing of patent applications related to Dysfunction for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dysfunction with additional patents listed. Browse our RSS directory or Search for other possible listings.